Pregnancy: Avaxim 80 U Pediatric: No relevant teratogenic data on animal are available.
In humans, up to now, the data is inadequate to assess teratogenic or foetotoxic risk of the vaccine against Hepatitis A when administered during pregnancy.
As a precautionary measure, it is preferable not to use this vaccine during pregnancy except in case of a major contamination risk.
Avaxim 160 U: No reliable data are available on teratogenesis in animals.
To date, there are no sufficiently relevant clinical data available to assess a potential vaccine-related malformation or foetotoxic effect of the hepatitis A vaccine, when it is administered during pregnancy. As a precautionary measure, it is preferable not to use this vaccine during pregnancy except in case of a major contamination risk.
Breast-feeding: Avaxim 80 U Pediatric: The effect of administration of AVAXIM 80U Pediatric during lactation has not been assessed. As AVAXIM 80U Pediatric is inactivated, any risk to the mother or the infant is improbable. The benefits versus the risks of administering AVAXIM 80U Pediatric during lactation should carefully be evaluated.
Avaxim 160 U: The effect of administering this vaccine during breast feeding has not been studied and its use during breast feeding is therefore not recommended.